Related Experiment Video
Updated: Aug 24, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
The effect of glycoprotein IIb/IIIa receptor inhibitor on the microcirculation in patients undergoing high-risk
Philip Wong1, Scott Harding, Ignacio Inglessis
1Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Insights
Tirofiban improves coronary microcirculation after high-risk stenting by preventing clot embolization. This glycoprotein IIb/IIIa inhibitor enhanced Doppler coronary flow reserve post-procedure, suggesting a protective effect on microvascular function.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Mechanisms of glycoprotein IIb/IIIa inhibitors in high-risk angioplasty remain unclear.
- Potential benefit may stem from preventing distal embolization of coronary thrombi.
Purpose of the Study:
- To assess tirofiban's impact on microcirculation using Doppler coronary flow reserve (CFR).
- To evaluate tirofiban's effect in patients undergoing high-risk coronary stenting.
Main Methods:
- Thirty-two patients with acute coronary syndrome or high-risk features were randomized.
- Group A received tirofiban; Group B received placebo.
- Coronary flow reserve measured by Doppler wire at baseline, post-balloon, and post-stenting.
Main Results:
- No significant difference in CFR at baseline or post-balloon angioplasty.
- Post-stenting CFR was significantly higher in the tirofiban group (2.94 vs. 2.25, p=0.014).
- Platelet aggregation was inhibited by over 94% in the tirofiban group.
Conclusions:
- Tirofiban protects and improves microcirculation in high-risk stenting patients.
- This improvement, measured by Doppler CFR, may be attributed to prevention of distal clot embolization.
- Tirofiban's microcirculatory effects could explain observed clinical benefits.
Objectives:
We evaluated the effect of the glycoprotein IIb/IIIa inhibitor, tirofiban, on the microcirculation measured by Doppler coronary flow reserve (CFR) in patients undergoing high-risk coronary stenting.
Background:
The mechanisms by which glycoprotein IIb/IIIa inhibitors benefit patients undergoing high-risk angioplasty are not fully understood. This may be due to prevention of distal embolization of the coronary clot at the site of angioplasty.
Methods:
Thirty two consecutive patients with acute coronary syndrome within 72 hours or with high-risk angiographic features were randomized into 2 groups. Group A (n = 17) received tirofiban (10 microg/kg bolus followed 0.15 microg/kg/min). Group B (n = 15) received placebo bolus and infusion. Coronary flow reserve was measured by Doppler wire technique at baseline, post balloon angioplasty and post-stenting. Platelet aggregation was measured at baseline, 10 minutes, 6 hours and 12 hours post bolus.
Results:
There was no significant difference in CFR between the groups at baseline and after balloon angioplasty. Post-stenting CFR, however, was significantly higher in the group pretreated with tirofiban (2.94 vs. 2.25, p = 0.014). The inhibition of platelet aggregation was 94% at 10 minutes, 97% at 6 hours and 94% at 12 hours in the tirofiban group.
Conclusion:
In patients undergoing high-risk coronary stenting, tirofiban protects and improves the microcirculation measured by Doppler wire technique. This may be due to prevention of distal embolization of clot by tirofiban and explain the clinical benefit.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...